Scientific evidence for every compound in the catalog. Each entry is DOI-linked, categorized by study phase and application, and documented transparently.
Retatrutide 12 mg led to a mean weight loss of 24.2% over 48 weeks, the highest published efficacy among anti-obesity agents.
HbA1c reduction up to 2.02% and 16.9% weight loss over 36 weeks in T2D patients.
Semaglutide 2.4 mg/week produced 14.9% mean weight loss vs. 2.4% placebo over 68 weeks, supporting Wegovy approval.
26% reduction in major adverse cardiovascular events in high-risk T2D patients over 104 weeks.
20% reduction in MACE in non-diabetic obese patients, the first obesity therapy with a primary CV outcome.
Tesamorelin 2 mg/day reduced visceral fat by 15.2% vs. placebo in 26 weeks, leading to Egrifta approval.
Relative 32% liver fat reduction over 6 months in HIV patients with NAFLD.
Single-dose CJC-1295 increased GH 2-10 fold for up to 6 days and IGF-1 for up to 11 days.
Selective GH release without ACTH, cortisol, or prolactin rise.
Sermorelin stimulates physiological pulsatile GH release, considered safer than exogenous rhGH in adult GHD.
Pentadecapeptide with documented GI ulcer healing, tendon repair, and VEGF-mediated angiogenesis in preclinical models.
BPC-157 promotes tenocyte migration and outgrowth in vitro via FAK-paxillin signaling.
Thymosin beta-4 modulates actin and supports wound healing, angiogenesis, and cardiac repair.
Clinical TB-500 programs show accelerated healing in corneal injury, pressure ulcers, and MI.
Human cathelicidin LL-37: antimicrobial, immunomodulatory, and wound-healing multi-target profile.
GHK-Cu modulates collagen and reactivates thousands of genes toward youthful expression patterns.
Foundational review of copper binding, anti-inflammation, and tissue regeneration by GHK.
SNAP-8 inhibits catecholamine release at the neuromuscular junction in vitro.
KPV tripeptide reduces inflammatory markers in colitis models via PepT1 uptake.
Mitochondrial MOTS-c improves insulin sensitivity and reduces high-fat-diet obesity in mice.
Elamipretide (SS-31) improved 6-minute walk distance by 64.5 m in primary mitochondrial myopathy.
Single-dose SS-31 acutely reduced LV end-systolic volume by 18 ml in HFrEF patients.
IV glutathione reduced UPDRS scores by 42% in early Parkinson's disease over 30 days.
Semax increases BDNF and dopamine in prefrontal cortex in rat models.
Intranasal Selank showed anxiolytic effects comparable to medazepam without sedation.
DSIP infusions reduced chronic insomnia symptoms and improved sleep architecture.
Pinealon tripeptide is neuroprotective under hypoxia and reduces ROS-induced neuronal death.
35-year overview of peptide-based aging modulation including telomerase and circadian effects.
Epithalon extended median lifespan in CBA mice by 12.3% and reduced spontaneous tumors.
FOXO4-DRI selectively induces senescent cell apoptosis and improves healthspan in aged mice.
Thymosin alpha-1 as immunomodulator with approved uses in hepatitis B/C in several countries.
PNC-27 binds membrane HDM-2 in tumor cells with selective cytotoxicity.
Adipotide reduced adiposity by 11% in rhesus monkeys via white adipose vasculature apoptosis.
